Buy Bio-Rad

Logo for stock BIO (Bio-Rad)

Amount

£
GBP

Latest price

$324.86
(£1.00 = $1.325)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$8.739B

P/E ratio

-13.62

EPS

-$24.014

Beta

1.18

Dividend rate

N/A

Dividend yield

N/A

About

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

CEO

Mr. Norman D. Schwartz

Employees

7,700

Sector

Industrials

Company HQ

HERCULES, United States of America

News

Logo for news article #0 (Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday)

Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

The Motley Fool

October 30, 2025

Logo for news article #1 (Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls)

Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls

BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.

Zacks Investment Research

October 30, 2025

Logo for news article #2 (Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript)

Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.

Seeking Alpha

October 29, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.